Peroxisome proliferator-activated receptor d (PPARd) is a critical regulator of energy metabolism in the heart. Here, we propose a mechanism that integrates two deleterious characteristics of heart failure, hypoxia and a metabolic shift toward glycolysis, involving the microRNA cluster miR-199a$214 and PPARd. We demonstrate that under hemodynamic stress, cardiac hypoxia activates DNM3os, a noncoding transcript that harbors the microRNA cluster miR-199a$214, which shares PPARd as common target. To address the significance of miR-199a$214 induction and concomitant PPARd repression, we performed antagomir-based silencing of both microRNAs and subjected mice to biomechanical stress to induce heart failure. Remarkably, antagomir-treated animals displayed improved cardiac function and restored mitochondrial fatty acid oxidation. Taken together, our data suggest a mechanism whereby miR-199a$214 actively represses cardiac PPARd expression, facilitating a metabolic shift from predominant reliance on fatty acid utilization in the healthy myocardium toward increased reliance on glucose metabolism at the onset of heart failure.
INTRODUCTION
Despite the remarkable metabolic flexibility of the heart regarding nutritional status and cardiac demand, several studies demonstrated abnormalities in cardiac lipid homeostasis and energy production as a consistent feature of heart failure (HF) (Barger and Kelly, 2000; Razeghi et al., 2001 ). Due to limited oxygen and fatty acid availability, the fetal heart mainly relies on anaerobic glucose utilization. In contrast, rising cardiac work and the abundance of fatty acids in the postnatal heart bring about increased reliance on mitochondrial fatty acid oxidation (FAO). Hemodynamically stressed hearts exhibit a return to the fetal metabolic pattern that is hallmarked by impaired mitochondrial FAO and a shift to further reliance on glucose metabolism (Rajabi et al., 2007; Razeghi et al., 2001 ). Due to the strict aerobic nature of the heart and the inability to generate sufficient energy under anaerobic conditions, reliance on glycolysis has a major impact on available ATP levels (Di Lisa et al., 2007) . As such, hypoxia is considered to be a characteristic of the failing heart (Giordano, 2005; Sabbah et al., 2000; Tanaka et al., 1994) .
Regulation of the metabolic profile by activity of the peroxisome proliferator-activated receptor d (PPARd) has been shown to play a role in the metabolic switch from FAO to glycolysis (Burkart et al., 2007) . Heart muscle-restricted deletion of PPARd resulted in progressive lipid accumulation, cardiac hypertrophy, and congestive heart failure (Cheng et al., 2004) . Conversely, selective overexpression of PPARd in the mouse heart provoked an increase in myocardial glucose utilization with no myocardial lipid accumulation due to preserved FAO and resistance to cardiac disease induced by ischemia reperfusion injury (Burkart et al., 2007) . These studies clearly illustrate the importance of PPARd signaling in energy homeostasis and pathogenesis of heart failure. Despite this, whether and how PPARd is regulated remains unclear.
Small noncoding RNAs ($18-24 nucleotides), such as microRNAs (miRNAs, miRs), have been shown to be a fascinating mechanism, coordinating complex programs of gene expression Thum et al., 2007; van Rooij et al., 2007) . By regulating the stability and translation of messenger RNAs by base-pairing with the 3 0 UTRs, miRNAs have been shown to impact gene expression in cardiovascular disease Thum et al., 2007) . In a comparative study among animal models of pathological cardiac remodeling, miR-199a and miR-214 showed increased expression in these animal models as well as in samples of failing human hearts (van Rooij et al., 2006) . In addition, expression of these miRNAs induced a hypertrophic response in cardiomyocytes, suggesting that miR-199a and miR-214 are involved in the processes leading to cardiac disease (van Rooij et al., 2006) . Despite their apparent role in cardiac remodeling, the mechanisms driving the regulation of miR-199a and miR-214 in the failing heart and how these miRNAs provoke deleterious cardiac remodeling remain undefined.
We report here that the miRNA cluster miR-199a$214, embedded in chromosome 1 in a large noncoding RNA, Dnm3os, actively represses PPARd. Furthermore, myocardial hypoxia provokes Dnm3os activation and concomitant miR-199a$214 expression. Increased expression of miR-199a and miR-214 promotes decreased cardiac PPARd expression, mitochondrial disarray and I band widening, and decreased mitochondrial fatty acid oxidative capacity. Conversely, antagomir-based silencing of miR-199a$214 in mice subjected to pressure overload derepressed cardiac PPARd levels, normalized mitochondrial fatty acid oxidation, and improved cardiac structure and function. Taken together, our data suggest a mechanism whereby myocardial hypoxia, a hallmark of heart failure, induces expression of members of the miRNA cluster miR-199a$214, which actively downregulate cardiac PPARd expression, provoking a switch toward a mitochondrial glycolytic metabolic profile that contributes to characteristics of heart failure.
RESULTS
The miR-199a:214 Cluster Is Increased in Human and Mouse Heart Failure Recent cardiac microRNA profiling studies from our group and others have shown that the expression of both miR-199a and miR-214 is increased in various models of heart failure (da Costa Martins et al., 2010; Leptidis et al., 2013; van Rooij et al., 2006) . Human miR-199a$214 is encoded by a large noncoding RNA, DNM3os, which is transcribed in the opposite strand of the DNM3 gene ( Figure 1A) . Both mature miRNAs, , are evolutionary conserved among several species ( Figure 1A ). Northern blot analysis confirmed that both miR-199a and miR-214 are upregulated in hearts from mice subjected to pressure overload by transverse aortic constriction (TAC) (Figures 1B and 1C) . Quantitative RT-PCR also showed an increase in DNM3os expression in TAC-operated mice, verifying the clustered expression of both miRs in failing mouse hearts ( Figure 1D ). An increased expression of DNM3os, along with the encoded miRNA cluster miR-199a$214, was also evident in biopsies of cardiac tissue from heart failure patients ( Figure 1E ).
Mechanistically, miR-199a and miR-214 are predicted to target multiple genes according to several public data sets. Interestingly, we identified PPARd as a predicted common target of both microRNAs. Indeed, investigation of the 3 0 UTR of PPARd revealed an evolutionarily conserved seed region for miR-214 in both human and mouse PPARd and a less-conserved seed region for miR-199a ( Figure 1F ). Next, we examined whether PPARd levels are affected in biopsies of cardiac tissue from heart failure patients. Western blot analysis in biopsies of cardiac tissue from heart failure patients showed lower protein levels of PPARd compared with human control heart tissue (Figures 1G and 1H) .
To further confirm the functionality of the seed regions of miR199a and miR-214, we fused the 3 0 UTR of PPARd to a luciferase -miR-199a and hsa-miR-214 , encoded by the large noncoding RNA DNM3os, located on the opposite strand in intron 14 of the dynamin-3 (DNM3) gene, on chromosome 1 in the human genome. The mature miR-199a and miR-214 strands are phylogenetically conserved. (B) Northern blot analysis of miR-199a and miR-214 expression in hearts from sham mice or mice subjected to transverse aortic constriction Figure S1 .
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MicroRNA Regulation of Cardiac Energy Metabolism reporter gene, generating miRNA expression reporter constructs ( Figure 1I ). Coexpression of synthetic miR-199a and/or miR-214 decreased PPARd 3 0 UTR reporter activity ( Figure 1J ), while mutating the seed regions for miR-214 in the PPARd 3 0 UTR reporter construct abrogated the inhibitory effect of miR-214 and miR-199a. Mutating the seed region for miR-199a only had an inhibitory effect on miR-199a transfection ( Figure 1J ; Figure S1A available online), indicating a dominant effect of miR-214 on PPARd repression and establishing the causative link between posttranslational control by the miRNA cluster miR-199a$214 on PPARd. To further verify whether increased miR-199a$214 levels are directly responsible for the decrease of PPARd protein levels in the failing hearts, we overexpressed synthetic precursors for miR-199a and/or miR-214 in a dose-dependent manner and observed efficient downregulation of endogenous PPARd expression ( Figure 1K ). Finally, we overexpressed a form of PPARd lacking a 3 0 UTR and demonstrated that this form of PPARd was insensitive to precursor transfection of miR-199a and miR-214 ( Figures 1L and 1M ). Taken together, these data demonstrate that miR-199a and miR-214, as well as their host gene Dnm3os, are increased in human and mouse heart failure and directly target PPARd.
Hypoxia Drives the Expression of miR-199a$214 through Hif1a/Twist1 Myocardial hypoxia has been associated with a variety of clinical conditions, including ischemic heart disease (IHD), systemic hypertension, and pathological cardiac hypertrophy, where the hypoxia-inducible transcription factor 1a (Hif1a) drives hypoxia-inducible gene expression (Lei et al., 2008; Rey and Semenza, 2010) . One Hif1a downstream mechanism employs the activation of the transcription factor Twist1 by binding directly to the hypoxia response element (HRE) in the Twist1 proximal promoter (Yang et al., 2008) . Interestingly, DNM3os has been identified as a target gene for the helix-loop-helix transcription factor Twist1 (Loebel et al., 2005) . To verify the functionality of this element, a luciferase reporter harboring the proximal DNM3os promoter region was generated and tested for Hif1a or Twist1 sensitivity ( Figure 2A ). The DNM3os-luc reporter demonstrated activation upon cotransfection with Hif1a or Twist1, while the enhancer box (E box)-mutated DNM3os-luc reporter construct showed no activation under the same conditions ( Figure 2B ).
Dnm3os homozygous-deficient mice die within 1 month of birth accompanied by skeletal abnormalities, defects in dorsal neural arches and spinous processes of the vertebrae, osteopenia, and reduced expression of its host genes miR-199a and miR-214 (Watanabe et al., 2008) . We reasoned that Dnm3os-deficient hearts may display derepression of PPARd due to the reduced expression of miR-199a$214. In line, western blotting demonstrated increased PPARd expression in Dnm3os-deficient hearts compared to hearts from wild-type (WT) littermates ( Figures 2C and 2D ). The premature death of juvenile Dnm3os-deficient mice precluded further functional studies.
The PPARd 3 0 UTR reporter also showed strong inhibition of luciferase activity under hypoxia, with peak activity on day 3 (Figure 2E) , confirming both the hypoxia-sensitive and microRNAmediated posttranslational regulation of PPARd. Quantitative RT-PCR confirmed a significant increase of endogenous miR199a, miR-214, and Dnm3os transcript abundance in cardiomyocytes upon exposure to hypoxia (2% O 2 ) ( Figure 2F ), indicating hypoxia as a primary stimulus for the expression of mature miR-199a and miR-214 via transcriptional regulation of DNM3os. Locked nucleotide acid (LNA) knockdown probes for miR-199a and/or miR-214 exhibited a strong and specific repression of the target miRs as quantified by PCR (Figures S1B and S1C). LNA-based knockdown of miR-199a and miR-214 inhibited the hypoxia-mediated PPARd downregulation (Figure 2G) . Interestingly, knockdown of miR-214 abrogated the hypoxia-induced downregulation of PPARd more effectively than when miR-199a was targeted ( Figure 2G ). These results indicate a more pronounced role for miR-214 than miR-199a in hypoxia-mediated knockdown of PPARd. Ventricular deletion of Hif1a in mice was previously used to implicate a Hif1a-PPARg axis in hypertrophy-induced PPARg activation, metabolic reprogramming, and contractile dysfunction (Krishnan et al., 2009 ). Accordingly, we tested whether cardiac-specific Hif1a deletion would also abrogate PPARd expression under baseline conditions or after pressure overload. Western blotting demonstrated that PPARd expression was reduced after pressure overload, and this reduction was efficiently prevented by cardiac-specific Hif1a deletion (Figures 2H and 2I) . In conclusion, the data demonstrate that hypoxia serves as an upstream stimulus for Dnm3os and miR-199a$214 expression in the heart in a hypoxia-and/or Hif1a-dependent manner.
Conditional Targeted Deletion of PPARd Causes Severe Cardiac Dysfunction
To investigate whether maintenance of PPARd expression is required for normal myocardial homeostasis and to bypass the early embryonic lethality of PPARd null mice (Barak et al., 2002) , we provoked deletion of a floxed PPARd (PPARd F/F ) allele using a tamoxifen-inducible Cre recombinase under the control of the cardiac-specific a-myosin heavy-chain promoter (aMHC). Specificity of PPARd gene deletion was shown by real-time RT-PCR for all three endogenous PPAR isoforms, demonstrating that our genetic intervention did not affect PPARa or PPARg transcripts, but resulted in a strong and selective downregulation of PPARd transcripts ( Figure S2A ). We forced PPARd gene deletion at the age of 8 weeks and noted that within 5 days after tamoxifen delivery, aMHC-MCM-PPARd F/F mice displayed signs of inactivity and a weak condition compared to all control groups. Indeed, up to 25% of tamoxifen-treated aMHC-MCM-PPARd F/F mice died within 1 week after initiation of the treatment, and this mortality rate increased to 75% during the following 2 weeks (data not shown). Upon autopsy, tamoxifen-treated aMHC-MCM-PPARd F/F displayed severely enlarged hearts ( Figure S2B ). Cardiac tissue from these mice revealed intricate features of clinical heart failure, including hypertrophied myofibers, myocyte disarray, and interstitial fibrosis in hearts ( Figure S2B ), which was reflected by doubling of heart weight at the whole-organ level ( Figure S2C ). These data demonstrate that conditional cardiacspecific deletion of PPARd in the adult heart causes rapid cardiac remodeling, which results in multiple clinical signs of end-stage heart failure and reduced survivability. Cardiac geometry and function was assessed noninvasively by echocardiography at 2 weeks after tamoxifen treatment ( Figure S2D ; Table S1 ). At this time point, tamoxifen-treated aMHC-MCM-PPARd F/F animals demonstrated a significant decline in cardiac contractility, as evidenced by a 50% decrease in fractional shortening ( Figure S2E ), and severe left ventricular dilation ( Figure S2F ). These data indicate that conditional cardiac-specific deletion of PPARd provoked progressive functional and geometrical deterioration consistent with a heart failure phenotype, including potent reactivation of stress-induced embryonic genes such as Acta1, Nppb, Myh7, and Nppa ( Figure S2G ). Moreover, we noted a substantial decrease in transcript abundance for Cd36 and hadha, without changes in Slc2a1 transcript abundance (Figure S2H) , indicating a reduction in fatty acid transport capacity and oxidation. Conclusively, deletion of PPARd in the adult heart induces rapid and spontaneous cardiac dysfunction, induction of fetal hypertrophic marker genes, and selective downregulation of genes involved in fatty acid metabolism.
miR-214 Silencing Improves Cardiac Contractility and Derepresses PPARd
Antagomirs are RNA-like oligonucleotides that are reverse compliment to mature microRNAs and harbor various modifications for ribonuclease (RNase) protection and pharmacologic properties such as enhanced tissue and cellular uptake. Antagomirs efficiently silence microRNAs in most tissues in vivo (Krü tzfeldt et al., 2005) . To intervene in the targeted downregulation of PPARd by miR-199a$214 in cardiac disease conditions, we subjected mice to transverse aortic constriction pressure overload -199a, miR-214, miR-199b, miR-107, miR-133a, miR-25, and miR-181a 
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MicroRNA Regulation of Cardiac Energy Metabolism for 6 weeks and treated them with antagomirs for either miR199a or miR-214 for 3 consecutive days at 3-week intervals (Figure 3A) . To verify silencing efficiency of antagomir-199a and antagomir-214, quantitative RT-PCR was performed ( Figures  3B and 3C ). The specificity of the antagomirs used was verified by measuring the expression of other microRNAs ( Figures 3B  and 3C ). Sham-operated mice treated with vehicle, antagomir199a, antagomir-214 showed no signs of histopathology or alterations in heart size ( Figures S3A-S3C ). Vehicle-treated mice showed substantial cardiac enlargement, displayed hypertrophied myofibers, myocyte disarray, and interstitial fibrosis upon hemodynamic stress ( Figure 3D ), and displayed significantly increased heart weights ( Figure 3E ). No significant reduction in heart weight was observed in antagomir-199a-or antagomir-214-treated mice that underwent TAC surgery ( Figures 3D and  3E ). Antagomir-199a-or antagomir-214-treated pressure-overloaded hearts displayed less hypertrophied myofibers, myocyte disarray, and reduced fibrosis, with the effects more pronounced for mice treated with antagomir-214 ( Figure 3D ). Analysis of cardiac function by M-mode echocardiography at 6 weeks demonstrated an increase in left ventricular internal diameter (LVID) in mice subjected to pressure overload and treated with vehicle, which was slightly reduced upon antagomir-214 treatment (Figures 3F and 3G) . Importantly, the decrease in systolic and diastolic contractility observed in vehicle-treated mice subjected to TAC surgery was significantly improved by either antagomir199a or antagomir-214 treatment (Figures 3H-3J ; Table 1 ). Furthermore, antagomir-214 treatment was able to fully derepress PPARd levels following hemodynamic stress (Figures 3K and 3L) . To analyze the effect of antagomir-214 treatment on metabolism, we performed RT-PCRs for both fatty acid and glucose marker genes. Cardiac pressure overload did not alter the expression of genes implicated in glucose metabolism (Figure 3M ). In contrast, pressure overload induced a pronounced reduction in key genes involved in fatty acid metabolism, including acyl-coenzyme A dehydrogenase, medium-chain (Acadm), CD36 antigen (Cd36), and diacylglycerol O-acyltransferase 2 (Dgat2), which were fully restored upon antagomir-214 treatment ( Figure 3N ). Antagomir-214 treatment did not influence the reactivation of stress-induced fetal genes, including Nppa, Nppb, Acta1, and Myh7 ( Figure S3D ). Taken together, these data demonstrate that single miR-199a or miR-214 
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MicroRNA Regulation of Cardiac Energy Metabolism antagomir-mediated silencing mildly improved cardiac remodeling and differentially restored cardiac contractility, PPARd expression, and key genes involved in fatty energy metabolism.
miR-199a$214 Silencing Attenuates Cardiac Remodeling and Dysfunction
Next, we intervened in miR-199a$214 induction in cardiac disease conditions by subjecting mice to transverse aortic constriction pressure overload for 6 weeks and treating them with antagomirs for both miR-199a and miR-214 for 3 consecutive days at 3-week intervals ( Figure 4A ). To ensure equal pressure gradients among the experimental groups, noninvasive pressure gradients across the transverse aorta were measured ( Figure 4B ). Vehicletreated mice showed substantial cardiac enlargement upon biomechanical stress ( Figure 4C ), whereas antagomir199a$214-treated mice displayed significantly reduced heart weights ( Figure 4D ). Sham-operated mice treated with vehicle or antagomir-199a$214 showed no signs of histopathology (Figure 4C ). In contrast, cardiac tissue of vehicle-treated mice subjected to pressure overload displayed hypertrophied myofibers, myocyte disarray, and interstitial fibrosis, while mice treated with antagomir-199a$214 displayed normal myocyte arrangement and significantly reduced hypertrophy and fibrosis ( Figure 4C ; Figure S4A ). Analysis of cardiac function by M-mode echocardiography at 6 weeks showed an increase in LVID and a proportional decrease in systolic contractility (FS) in mice subjected to pressure overload and treated with vehicle (Figures 4E-4G ; Table 2 ). Importantly, treatment with antagomir-199a$214 derepressed PPARd levels even in sham-operated animals and restored PPARd expression following hemodynamic stress (Figures 4H and 4I ), but did not influence PPARa expression (Figure S4B ), further underscoring a specific role for PPARd. To analyze the effect of antagomir treatment on metabolism in these hearts, we performed RT-PCRs for both fatty acid and glucose marker genes. Neither cardiac pressure overload nor antagomir-199a$214 treatment altered the expression of genes implicated in glucose metabolism, including those encoding solute carrier family 2 facilitated glucose transporter member 1 and member 4 (Slc2a1, Slc2a4) and hexokinase 1 (Hk1), in mouse hearts exposed to pressure overload ( Figure 4J ). In contrast, cardiac pressure overload induced pronounced changes in key genes involved in fatty acid metabolism, including acyl-coenzyme A dehydrogenase, long chain (Acadl) and Acadm, indicating restoration of fatty acid metabolism ( Figure 4K ).
miR-199a$214 Silencing Restores Mitochondrial Fatty Acid Metabolism
Mitochondria play a crucial role in maintaining the energy homeostasis in the heart muscle (Marin-Garcia et al., 2001) . Since in vivo antagomir-based silencing of miR-199a and miR-214 resulted in a restoration of PPARd expression and genes involved in fatty acid metabolism, we investigated whether mitochondrial ultrastructure was influenced. Transmission electron microscopy (TEM) assessment of heart sections showed salient mitochondrial disarray in pressure-overloaded mouse hearts ( Figure 5A ). Treatment with antagomir-199a$214 normalized mitochondrial alignment in mice and restored I band width (Figure 5A) , with unaltered expression of mitochondrial complex I-V components in pressure overload-induced cardiac dysfunction ( Figure 5B ; Figure S5A ). We next assessed mitochondrial respiration in isolated cardiac mitochondria, fueled by two types of substrates: the carbohydrate-derived substrate pyruvate and the fatty acid-derived substrate palmitoyl-CoA (in the presence of carnitine) (Hoeks et al., 2010) . Briefly, after the addition of substrate, maximal ADP-stimulated (state 3) respiration was determined. Subsequently, the leak rate (i.e., the respiratory rate in the presence of the ATP-synthase inhibitor oligomycin [state 4]) and the maximal respiratory capacity (i.e., the respiratory rate after addition of the chemical uncoupler FCCP [state U]) were assessed. These respiratory analyses revealed clear 
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MicroRNA Regulation of Cardiac Energy Metabolism substrate-dependent changes in the mitochondrial oxidative capacity of the heart upon pressure overload and treatment with antagomir-199a$214 ( Figures 5C and 5D ). Thus, when isolated cardiac mitochondria were fueled with the carbohydrate-derived substrate pyruvate, ADP-stimulated, oligomycin-insensitive as well as FCCP-induced respiration was similar across all groups ( Figure 5C ). On the other hand, pressure overload considerably reduced mitochondrial fatty acid oxidative capacity, as evidenced by a significant reduction in both the ADP-stimulated (À25%) and the maximally uncoupled respiration (À20%) upon the fatty acid substrate palmitoyl-CoA ( Figure 5D ). The leak rate (state 4 respiration) remained unaffected by pressure overload. Interestingly, the reduced fatty acid oxidative capacity upon pressure overload was completely restored by (E) Differentially expressed proteins detected by cardiac proteomics and computational analysis of the potential miR-214 seed regions presence and/or the conserved number of PPRE sites present in the 10 kb promoter region. Depicted in orange are mitochondrial located genes. (F) Model depicting the activation of hypoxia-mediated expression of the miR-199a$214 cluster under cardiac stress via the Hif1a/Twist1 pathway, leading to the targeting and subsequent downregulation of PPARd. This results in perturbed mitochondrial fitness and reduced fatty acid metabolism. Antagomir-mediated silencing of miR-199a and miR-214 derepresses PPARd expression and normalizes cardiac energy homeostasis. *p < 0.05 versus corresponding control group; #p < 0.05 versus corresponding experimental group (error bars are SEM). See also Figure S5 and Table S2. antagomir-based silencing of the miRNA cluster miR-199a$214, indicating that both ADP-stimulated and the maximally uncoupled respiration rate upon palmitoyl-Coa + carnitine was similar to the respective respiration rates observed in control animals. Single microRNAs likely simultaneously influence expression of up to 100 target genes (Hu et al., 2012) . Given the strong restoration of mitochondrial fatty acid oxidative capacity and cardiac contractility of the hemodynamically challenged heart achieved by antagomir-199a$214, we interrogated (using an unbiased proteomics screen) whether additional proteins were influenced either directly by silencing miR-199a$214 or indirectly by reactivation of PPARd (Table S2) . Accordingly, we detected an additional 20 differentially expressed proteins (five of which were mitochondrial) in pressure-overloaded hearts upon miR-199a$214 silencing, many of which harbored potential miR-199a ( Figure S5B ) or miR-214 seed regions and/or contained PPAR response elements (PPREs) in their promoter region ( Figure 5E ), suggesting that miR-199a$214 silencing provokes specific alterations on the cardiac mitochondrial proteome in addition to PPARd derepression. Altogether, our data suggest a mechanism whereby myocardial hypoxia, a characteristic of heart failure, induces expression of members of the miRNA cluster miR-199a$214 that actively downregulate several mitochondrial and cardiac targets including PPARd, provoking a switch toward a glycolytic metabolic profile that contributes to heart failure ( Figure 5F ).
DISCUSSION
Although the regulation of metabolism is modulated by a variety of factors, the molecular mechanisms that drive the metabolic shift in the failing heart are still incompletely understood. The hemodynamically challenged myocardium exhibits a return to the fetal metabolic pattern that is hallmarked by impaired mitochondrial fatty acid oxidation and a shift to further reliance on glucose metabolism (Rajabi et al., 2007; Razeghi et al., 2001) . Here, we propose a mechanism that integrates two characteristics of heart failure, hypoxia and a metabolic shift toward glycolysis, involving a microRNA cluster and a variety of target genes including PPARd. We demonstrate that under hemodynamic stress, regional hypoxia in the heart activates DNM3os, a noncoding RNA transcript that harbors the miRNA cluster miR199a$214, in a HIF-dependent and/or HIF-independent manner. As one mechanistic explanation, the miRNA-mediated repression of PPARd activity participates in a specific defect in mitochondrial respiration using fatty acids as substrate, resulting in a metabolic shift of the heart from predominant reliance on fatty acid utilization in the healthy myocardium toward increased reliance on glucose metabolism in the failing heart. Recently, Gan and colleagues demonstrated that muscle-specific overexpression of PPARd increased glucose oxidation in mitochondria through the reprogramming of glucose utilization pathways via interaction with the exercise-inducible AMP-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A) (Gan et al., 2011) . This effect may be selective for skeletal muscle, given that in our study we did not observe enhanced glucose utilization after reactivation of PPARd in the hemodynamically stressed heart, but further lend evidence toward a role for PPARd in the regulation of mitochondrial fueling.
Targeted expression of an activated form of PPARd in skeletal muscle induced a muscle fiber type switch, hereby conferring resistance to obesity and improved metabolic profiles, in part through increased mitochondrial function (Wang et al., 2004) . Furthermore, conditional transgenic mice expressing a constitutively active form of PPARd in cardiomyocytes displayed enhanced mitochondrial capacity at baseline and under conditions of pressure overload (Liu et al., 2011) . In contrast, Wang et al. (2010) demonstrated that inducible gene targeting of PPARd in the adult heart resulted in decreased mitochondrial function, concomitant with a hypertrophic response and decreased cardiac function. These data confirm our findings that restoring PPARd levels in the heart maintains oxidative capacity of mitochondria and protects against heart failure. Conversely, our proteomics analysis of the miR-199a$214-silenced myocardium has given us a first unbiased indication of additional factors further involved in the phenotypic changes we observed. As expected, a large number of them are mitochondria specific (Coq9, Dlat, Uqcrfs1, Ndufv2, Hspe1, and Nnt) ; however, their precise regulation by this pathway remains to be experimentally validated. As a first attempt to elucidate their potential dependency on a miR-199a$214/PPARd circuitry, we identified a number of potential PPREs as well as a number of potential binding sites for miR-199a and/or miR-214. These data suggest possible first or second degree interactions with our proposed mechanism and open up future studies to elucidate their function in cardiac energy metabolism.
As a key determinant of progression to heart failure, hypoxia is postulated to be a driving force for adverse cardiac remodeling. Pressure overload and ischemia often occur together clinically, as in patients with hypertension and coronary disease. As miR-214 was recently demonstrated to act as a regulator of cardiomyocyte Ca 2+ homeostasis and survival during acute cardiac ischemia-reperfusion injury (Aurora et al., 2012) , the possible use of future miR-214 therapeutics may be of more benefit in chronic cardiac (hypertrophic) remodeling processes rather than acute cardiac ischemic conditions. Indeed, pathologically hypertrophied hearts show significant decreased capillary density and associated hypoxia (Friehs et al., 2004) . In a mouse model with cardiomyocyte-restricted deletion of the von Hippel-Lindau protein (VHL), a component of the E3 ubiquitin ligase that inhibits Hif1a, chronic activation of the Hif1a hypoxia response pathway is observed (Lei et al., 2008) , resulting in progressive cardiac degeneration with lipid accumulation and decreased mitochondrial number leading to severe heart failure. Next to its role in modulating the fate of mesenchymal cell population during development, Twist1 has been also implicated in a wide range of neoplasias, including gastric, liver, and breast cancers (Karreth and Tuveson, 2004; Mironchik et al., 2005; Niu et al., 2007) . Analysis of Twist1 expression showed a ubiquitous expression in various mouse tissues with diverse expression patterns, with relatively high expression in the cardiac ventricle (Lu et al., 2011) , which is in line with the proposed regulatory role for Dnm3os expression. Dnm3os-deficient mice display defects in skeletal formation and body growth during embryonic development (Watanabe et al., 2008) . Taken together, our data show that miR-199a and miR-214 play a pivotal role in PPARd-mediated regulation of cardiac mitochondrial substrate fluxes with impact on cardiac structure and function, resulting in a metabolic shift of the heart from predominant reliance on fatty acid utilization in the healthy myocardium toward increased reliance on glucose metabolism in the failing heart. Our observations indicate that human heart failure arises from derangements in gene regulatory circuits, where molecular understanding of these circuits will aid in predicting sites of therapeutic intervention.
EXPERIMENTAL PROCEDURES
Human Heart Samples Tissue was taken from the left ventricular free wall of patients with end-stage heart failure secondary to ischemic heart disease or from patients undergoing heart transplantation because of terminal heart failure. Control tissue was taken from the left ventricular free wall of refused donor hearts.
Mouse Models
Mouse models included Dnm3os lacZ mice (Watanabe et al., 2008) , Hif1a
F/F mice (Ryan et al., 1998) interbred with myosin light chain 2v (MLC2v)-Cre mice (Chen et al., 1998) (Krishnan et al., 2009) , and PPARd F/F mice (Jackson Laboratories) interbred with mice harboring a tamoxifen-regulated form of Cre recombinase (MerCreMer) under control of the murine Myh6 promoter (Sohal et al., 2001 ). All protocols were performed according to institutional guidelines and approved by local Animal Care and Use Committees.
Aortic Banding and Transthoracic Echocardiography
Transverse aortic constriction or sham surgery was performed in 2-to 3-month-old BL6CBAF1 mice by subjecting the aorta to a defined 27G constriction between the first and second truncus of the aortic arch as described previously Rockman et al., 1991) . Noninvasive, Doppler echocardiographic analysis was performed as described previously in detail (da Costa Martins et al., 2010) .
Antagomir Administration
Antagomirs, 20-23 nt long RNA oligos complementary to miR-199a or miR-214, were purchased from Fidelity Systems or Integrated DNA Technologies and synthesized essentially as previously described (Krü tzfeldt et al., 2005) , except that cholesterol was linked through a hydroxyprolinol linkage. All antagomirs were 2 0 -Ome modified, contained a 3 0 cholesterol-TEG (15 atom triethylene glycol), 2 phosphorothioate (PT) bonds at the very first 5 0 end, and PT bonds between the last 3 0 bases. All antagomirs were HPLC purified and desalted before use.
Northern Blot Analysis
Northern blot analysis was performed as described previously (da Costa Martins et al., 2010) using 3 0 -digoxigenin-labeled locked nucleic acid oligonucleotides for hsa -miR-199a, hsa-miR-214, mmu-miR-199a, mmu-miR-214 , or U6 small nuclear RNA (Rnu6-2) and detected with an antibody to 3 0 -digoxigenin (Roche).
MicroRNA and mRNA Real-Time PCR Primer sequences are described in Table S3 . Real-time PCR was performed using miScript SYBR Green PCR Kit (QIAGEN) on a Bio-Rad iCycler.
Primary Cardiomyocytes, Transient Transfections, and Luciferase Reporter Assays Cardiomyocyte cultures were isolated by enzymatic dissociation of 1-to 2-day-old neonatal rat hearts, as described previously (De Windt et al., 2000) , and transfected with miR-199a, miR-214, or scrambled-miR precursor molecules (Ambion) using oligofectamine (Invitrogen). Human embryonic kidney (HEK) 293 cells were transfected with pMIR reporter plasmids harboring the 3 0 UTR of human PPARd using FuGENE 6 (Roche) reagent, followed by transfection with miR-199a, miR-214, or scrambled miR precursor molecules using oligofectamine. For cotransfection assays, pGL3-Dnm3os promoter constructs were cotransfected with constructs expressing a stabilized form of Hif1a and/or Twist1. pRL-TK, containing the thymidine kinase promoter driving Renilla luciferase, was included to correct for transfection efficiency.
Western Blot Analysis
Immunoprecipitation, SDS PAGE electrophoresis, and blotting were performed as described previously (De Windt et al., 2000) . Primary antibodies that were used for western blotting include polyclonal anti-PPAR-delta (Abcam), anti-PPAR-alpha (Abcam), monoclonal anti-GAPDH (Chemicon), and monoclonal total OXPHOS cocktail (MitoSciences), followed by corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies and enhanced chemiluminescence (ECL) detection.
Histological Analysis and Immunofluorescence Microscopy
Hearts were arrested in diastole, paraffin embedded, sectioned at 4 mm, and stained with fluorescein isothiocyanate (FITC)-labeled wheat germ agglutinin (WGA), hematoxylin and eosin (H&E), Sirius red, or biotinylated Griffonia simplicifolia lectin I (GS-I) to visualize cardiac vascularization.
Isolation of Cardiac Mitochondria and Mitochondrial Respirometry
Cardiac tissue was processed for mitochondrial isolation by mechanical Potter homogenization, repeated centrifugation, and gentle resuspension. Mitochondrial respiratory rates were analyzed using an oxygraph (OROBOROS Instruments) (Hoeks et al., 2010) .
Proteomics Analysis
Cardiac tissue was diced, PBS washed with proteinase inhibitors (SigmaAldrich), and incubated with 0.1% SDS, and the SDS solution was stored frozen. Next, samples were incubated with 4 M guanidine hydrochloride with proteinase inhibitors, proteins were precipitated by centrifugation, and the pellets were kept at À20 C. The gel bands were subjected to in-gel digestion with trypsin, and tryptic peptides were separated on a Nanoflow LC System (Dionex UltiMate 3000), eluted with a 40 min gradient, and the column (Dionex PepMap C18) was coupled to a nanospray source (PicoView). Spectra were collected from an ion trap mass analyzer (LTQ Orbitrap XL). Tandem mass spectrometry (MS/MS) was performed on the top six ions in each MS scan using the data-dependent acquisition mode with dynamic exclusion enabled. MS spectra were separately analyzed in MaxQuant Software. To construct a MS/ MS peak list file, up to the top eight peaks per 100 Da window were extracted and submitted to search against a concatenated forward and reverse version of the UniProtKB/Swiss-Prot mouse database. A principal component analysis was performed using the normalized high/low ratios of all proteins from all samples. Significant differences were identified using the Bioconductor limma package and Bayesian statistics to moderate variance across proteins and calculate a p value.
Statistical Analysis
The results are presented as mean ± SEM. All statistical analyses were performed with Prism software (GraphPad), consisting of an ANOVA test followed by Tukey's post hoc test when group differences were detected at the 5% significance level or Student's t test when comparing two experimental groups. Differences were considered significant when p < 0.05.
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